Phibro Animal Health (NASDAQ:PAHC) Raised to Strong-Buy at StockNews.com

Phibro Animal Health (NASDAQ:PAHC) was upgraded by equities researchers at StockNews.com from a “buy” rating to a “strong-buy” rating in a research report issued on Tuesday.

Other research analysts have also issued research reports about the company. Bank of America raised their price objective on Phibro Animal Health from $13.00 to $15.00 and gave the company an “underperform” rating in a report on Friday, August 30th. Barclays raised their target price on Phibro Animal Health from $13.00 to $20.00 and gave the stock an “underweight” rating in a research note on Tuesday. Finally, JPMorgan Chase & Co. initiated coverage on Phibro Animal Health in a research report on Tuesday, September 10th. They set a “neutral” rating and a $22.00 price objective for the company. Three analysts have rated the stock with a sell rating, one has given a hold rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $16.50.

Phibro Animal Health Stock Down 1.9 %

NASDAQ:PAHC traded down $0.49 during mid-day trading on Tuesday, reaching $25.06. The company’s stock had a trading volume of 314,254 shares, compared to its average volume of 157,197. Phibro Animal Health has a 1 year low of $9.40 and a 1 year high of $25.98. The stock has a fifty day moving average of $22.46 and a 200-day moving average of $19.52. The firm has a market capitalization of $1.01 billion, a PE ratio of 58.28, a price-to-earnings-growth ratio of 0.58 and a beta of 0.51. The company has a quick ratio of 1.64, a current ratio of 3.23 and a debt-to-equity ratio of 1.81.

Phibro Animal Health (NASDAQ:PAHC) last announced its earnings results on Wednesday, August 28th. The company reported $0.41 EPS for the quarter, topping analysts’ consensus estimates of $0.34 by $0.07. Phibro Animal Health had a net margin of 1.67% and a return on equity of 21.59%. The business had revenue of $273.16 million during the quarter, compared to the consensus estimate of $262.44 million. Equities research analysts forecast that Phibro Animal Health will post 1.63 earnings per share for the current year.

Insider Activity at Phibro Animal Health

In other Phibro Animal Health news, Director E Thomas Corcoran bought 5,000 shares of the business’s stock in a transaction on Wednesday, September 4th. The shares were purchased at an average price of $20.02 per share, with a total value of $100,100.00. Following the purchase, the director now directly owns 25,000 shares of the company’s stock, valued at approximately $500,500. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 50.07% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. CWM LLC lifted its position in shares of Phibro Animal Health by 89.8% in the second quarter. CWM LLC now owns 2,188 shares of the company’s stock worth $37,000 after buying an additional 1,035 shares during the last quarter. nVerses Capital LLC acquired a new position in Phibro Animal Health in the 3rd quarter valued at approximately $70,000. Summit Securities Group LLC acquired a new position in Phibro Animal Health in the 2nd quarter valued at approximately $83,000. China Universal Asset Management Co. Ltd. raised its holdings in Phibro Animal Health by 63.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,912 shares of the company’s stock valued at $88,000 after acquiring an additional 1,522 shares in the last quarter. Finally, Illinois Municipal Retirement Fund grew its stake in shares of Phibro Animal Health by 7.2% in the 1st quarter. Illinois Municipal Retirement Fund now owns 11,430 shares of the company’s stock valued at $148,000 after purchasing an additional 765 shares during the period. Hedge funds and other institutional investors own 99.34% of the company’s stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.